BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm 2017;2017:5198798. [PMID: 28512387 DOI: 10.1155/2017/5198798] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarantis P, Trifylli E, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. IJMS 2022;23:13612. [DOI: 10.3390/ijms232113612] [Reference Citation Analysis]
2 Ailia MJ, Yoo SY. In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review. Vaccines (Basel) 2022;10:1541. [PMID: 36146619 DOI: 10.3390/vaccines10091541] [Reference Citation Analysis]
3 Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. J Hepatol 2022:S0168-8278(22)03003-3. [PMID: 35988688 DOI: 10.1016/j.jhep.2022.08.003] [Reference Citation Analysis]
4 Chen S, Chen H, Zhang Y, Li W. Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:772509. [DOI: 10.3389/fonc.2022.772509] [Reference Citation Analysis]
5 Choudhri A. IR Liver-Directed Therapies for HCC. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_5] [Reference Citation Analysis]
6 Sinha V, Shinde S, Baghel VS, Vishvakarma NK, Shukla D, Tiwari AK, Dixit AK, Pandey SK, Dwivedi S, Singh M, Dixit V. Therapeutic options for the management of hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00018-5] [Reference Citation Analysis]
7 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Bukhari B, Naveed M, Makhdoom SI, Jabeen K, Asif MF, Batool H, Ahmed N, Chan YY. A Comparison Between Organic and Inorganic Nanoparticles: Prime Nanoparticles for Tumor Curation. NANO 2021;16:2130011. [DOI: 10.1142/s1793292021300115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Reference Citation Analysis]
10 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
11 Martini G, Ciardiello D, Paragliola F, Nacca V, Santaniello W, Urraro F, Stanzione M, Niosi M, Dallio M, Federico A, Selvaggi F, Della Corte CM, Napolitano S, Ciardiello F, Martinelli E. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4719. [PMID: 34572944 DOI: 10.3390/cancers13184719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
13 Choudhri A. IR Liver-Directed Therapies for HCC. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_5-1] [Reference Citation Analysis]
14 Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? Crit Rev Oncol Hematol. 2021;157:103167. [PMID: 33271389 DOI: 10.1016/j.critrevonc.2020.103167] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
15 Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
17 Jeong SN, Yoo SY. Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity. Cancers (Basel) 2020;12:E1070. [PMID: 32344903 DOI: 10.3390/cancers12051070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
18 Asp P, Guha C, Chowdhury NR, Chowdhury JR. Liver‐Directed Gene Therapy. The Liver 2020. [DOI: 10.1002/9781119436812.ch73] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hilmi M, Vienot A, Rousseau B, Neuzillet C. Immune Therapy for Liver Cancers. Cancers (Basel) 2019;12:E77. [PMID: 31892230 DOI: 10.3390/cancers12010077] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
20 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
21 Yoo SY, Badrinath N, Lee HL, Heo J, Kang DH. A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma. Cancers (Basel) 2019;11:E1667. [PMID: 31717883 DOI: 10.3390/cancers11111667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 92] [Cited by in F6Publishing: 100] [Article Influence: 30.7] [Reference Citation Analysis]
23 Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. Liver Cancer 2019;8:326-40. [PMID: 31768343 DOI: 10.1159/000494843] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
24 Bahreyni A, Ghorbani E, Fuji H, Ryzhikov M, Khazaei M, Erfani M, Avan A, Hassanian SM, Azadmanesh K. Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives. J Cell Biochem 2019;120:2766-73. [PMID: 30321455 DOI: 10.1002/jcb.27661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]